Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma

Authors:

Abstract
Risk‐adapted, response‐based therapies for pediatric Hodgkin lymphoma have resulted in 5‐year survival exceeding 90%. Although high‐dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk‐stratified, response‐based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579–586.

This publication has 44 references indexed in Scilit: